Pulse Biosciences Inc SEC Filings

Pulse Biosciences (PLSE) announced first patient enrollment in its NANOCLAMP AF clinical trial, a single-arm, prospective multicenter study evaluating the safety and effectiveness of the nPulse Cardiac Surgical System for treating atrial fibrillation during concomitant surgical procedures.

The company reported that the first procedure was successfully completed at St. Helena Hospital in St. Helena, California. A related press release was furnished as Exhibit 99.1. This update reflects early clinical progress for the cardiac surgical application of the company’s pulsed-field technology.

Pulse Biosciences reported late-breaking first‑in‑human feasibility results for its nPulse™ Cardiac Surgical System. The study has treated 44 patients across three investigators, with an initial cohort of 24 patients evaluated by electroanatomical mapping about ~3 months after ablation. Key clinical outcomes: posterior box isolations were acutely successful in 100% of cases in the high‑dose cohort; pulmonary vein isolation (PVI) success per vein at ~3 months was 94% (63 of 67); average total ablation time was 50 seconds with an average of 13 applications. No esophageal or phrenic nerve damage and no ablation‑related severe or major adverse events were reported. The company attached a press release as Exhibit 99.1 describing presentation of these results at the European Association for Cardio‑Thoracic Surgery annual meeting.

Pulse Biosciences insider transactions on 10/02/2025: The company's Chief Commercial Officer exercised 4,600 stock options at an exercise price of $1.53 and simultaneously sold those 4,600 shares at a weighted average price of $18.53 per share under a Rule 10b5-1 trading plan. After these transactions the reporting person beneficially owned 43,298 shares of common stock and held options to acquire 425,000 shares that expire on 09/23/2032. The Form 4 discloses the 10b5-1 plan adoption date of 05/14/2025 and notes the option grant date of 09/23/2022 with a four-year vesting schedule.

PULSE BIOSCIENCES reported director compensation and a leadership update. The company's board ratified awards granted August 9, 2024, comprising three grants of 200,000 option shares each for a total of 600,000 options. The filing notes 2,753,901 broker non-votes on an item reported as "Against" and includes an entry of "N/A" for related fields. It also states that Mr. LaViolette became President and Chief Executive Officer on January 9, 2025 and remains an ex officio member of the Strategic Advisory Committee.

Pulse Biosciences (PLSE) insider transactions by Kevin Patrick Danahy. The reporting person, the company's Chief Commercial Officer, executed sales and option-related transactions on September 18–19, 2025 under a Rule 10b5-1 trading plan adopted May 14, 2025. On 9/18/2025 he acquired 20,000 shares at $1.53 via option exercise and sold 20,000 shares at a weighted average price of $18.49, leaving 43,298 shares beneficially owned. On 9/19/2025 he exercised 400 shares at $1.53 and sold 400 shares at $18.48; post-transactions his direct beneficial ownership of common stock reported in Table I was 43,298 shares. Options granted 9/23/2022 covering 450,000 shares vest 25% annually; 20,400 options were exercised in these transactions.

Darrin Uecker, Pulse Biosciences (PLSE) Chief Technology Officer and director, reported multiple scheduled trades under a Rule 10b5-1 plan on September 16-17, 2025. He sold 25,000 shares on 9/16 and 20,000 shares on 9/17 at weighted average prices of $16.28 and $16.21 respectively, and purchased shares the same days at an exercise price of $4 under stock options and via market purchases. After the reported transactions his beneficial ownership of common stock is stated as 284,406 shares. Several $4 stock options with various exercisable dates are listed, and the Form notes the trades were executed pursuant to a 10b5-1 plan adopted June 12, 2025.

Form 144 filed for Pulse Biosciences, Inc. (PLSE) reports a proposed sale of 25,000 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $406,750.00. The filing states the shares were acquired and paid for on 09/18/2025 by exercise of stock options from the issuer, and the approximate date of sale is also listed as 09/18/2025.

The filing lists 67,278,347 shares outstanding, and no other sales by the reporting person in the past three months were reported. The filer represents there is no undisclosed material adverse information and includes the standard signed certification language on trading plans and criminal penalties for false statements.

PULSE BIOSCIENCES insider transactions: Darrin Uecker, Chief Technology Officer and director, executed option exercises and sales under a Rule 10b5-1 plan adopted June 12, 2025. On 09/11/2025, 09/12/2025 and 09/15/2025 he exercised three separate $4 stock option tranches of 25,000 shares each and contemporaneously sold 25,000 shares on each date. The reported weighted-average sale prices ranged by date: $14.41–$15.14 (09/11 weighted $14.78), $13.80–$14.76 (09/12 weighted $14.32), and $15.18–$17.20 (09/15 weighted $15.77). Following the transactions the filings show beneficial ownership positions reported in the Form 4 tables (e.g., 122,872 shares on the non-derivative table after sales). The options became fully vested on September 8, 2019 per the employment agreement.

Pulse Biosciences (PLSE) reported a Form 144 notice showing a proposed sale of 120,000 common shares by means of a broker, with an aggregate market value of $1,772,400 and an approximate sale date of 09/11/2025 on NASDAQ. The filing states the shares were acquired and paid for on 09/11/2025 through the exercise of stock options issued by the company, with payment made in cash. The broker listed is Morgan Stanley Smith Barney LLC. The filer also disclosed two prior open-market sales by the same person in June 2025 totaling 30,000 shares for gross proceeds of $485,700. The notice includes the standard representation that the seller is unaware of any undisclosed material adverse information.